Occurrence of Existing BCR-ABL Baseline Mutations and Associated Haplotype (NmR) Among CML Patients with Diverse IM Response: A Hospital-based Study from North-East India.

Highly polymorphic BCR-ABL kinase domains have been reported to harbor more than a hundred mutations, and among these, 40-60% have been identified as influencers of imatinib mesylate (IM) resistance. The emergence of IM resistance poses a significant challenge in the management of Chronic Myeloid Leukemia (CML). M351T (rs121913457), E255K (rs387906517), and Y253H (rs121913461) are of particular clinical significance due to their association with high-level imatinib resistance.

Epigenetic Modulation of DDIT3 and MGMT Expression Acts Synergistically with Resistance to Imatinib towards CML Disease Progression: A Hospital based Study.

Introduction: Imatinib Mesylate is an authenticated drug that aids in the treatment of Chronic Myeloid Leukaemia and Philadelphia patients which is recognized as a BCR-ABL tyrosine kinase inhibitor. Indeed, DNA Methylation occupies a key role in the stability of chromosomes.

Objective: Changes in the methylation status of genes may impart to the advancement of Chronic Myeloid Leukaemia.

An assessment of childhood cancer care services in India - gaps, challenges and the way forward.

Background: Childhood cancers are emerging as an essential concern in India where there is lack of a specific programme component or policy to address childhood cancer control. There is limited information on the status and quality of childhood cancer care services in India. This paper describes the childhood cancer care services available at secondary and tertiary-level hospitals in India through a cross sectional study design.

Low circulatory Fe and Se levels with a higher IL-6/IL-10 ratio provide nutritional immunity in tuberculosis.

Tuberculosis (TB) patients show dysregulated immunity, iron metabolism, and anemia. In this study, circulatory cytokines, trace metals, and iron-related proteins (hepcidin, ferroportin, transferrin, Dmt1, Nramp1, ferritin, ceruloplasmin, hemojuvelin, aconitase, and transferrin receptor) were monitored in case (active tuberculosis patients: ATB) and control (non-tuberculosis: NTB and healthy) study populations ( = 72, male: 100%, mean age, 42.94 years; range, 17-83 years).

Molecular detection of Orientia tsutsugamushi strains circulating in Nagaland.

The antigenic heterogeneity of Orientia in India is still unknown in many disease endemic areas. The present study aims to characterize the strains of O. tsutsugamushi circulating in Nagaland, Northeast India.

Rickettsiae in fleas infesting domestic pets of eastern Himalayan terrains of India.

Background: Flea-borne rickettsioses have been limitedly explored in the Indian sub-Himalayan belt, including the North Eastern Region (NER) of India. This study investigates the presence of rickettsiae hosts and their probable pathogens in the disease-endemic hilly state of the NER of India.

Methods: Entomological surveys were carried out in disease-reporting localities in a hilly state in India.

Intron 2 deletion generated the HLA-C*08:01:01:05 allele in a Sumi individual from Nagaland, North-East India.

HLA-C*08:01:01:05 differs from HLA-C*08:01:01:02 by one nucleotide deletion (T > -) at position 674 in intron 2.

The novel HLA-DPA1*01:03:01:21 allele in an individual of the Ao tribe from Nagaland, North-East India.

A single nucleotide change (C to T) in HLA-DQB1*01:03:01:03 results in the novel allele, HLA-DPA1*01:03:01:21.

Genetic Polymorphisms Along with Dietary and Environmental Factors Enhance the Susceptibility to Nasopharyngeal Carcinoma in Nagaland of Northeast India.

This study investigated the association of seven widely known DNA repair gene polymorphisms (hOGG1 Ser326Cys, XRCC1 Arg194Trp, XRCC1 Arg280His, XRCC1 Arg399Gln, XPC Val499Ala, XPD Lys751Gln and ERCC1 Cys8092Ala) with dietary and environmental factors for Nasopharyngeal Carcinoma (NPC) susceptibility in Nagaland of Northeast India. The genotypes were determined in 128 NPC patients and 180 healthy controls by PCR-RFLP. XRCC1 Arg280His, XPC Val499Ala and ERCC1 Cys8092Ala were found to be associated with NPC risk.

The novel HLA-C*07:02:01:97 allele identified in a Chang tribal individual from Nagaland, North-East India.

Two nucleotide changes in the 3'-UTR of HLA-C*07:02:01:01 results in the novel allele, HLA-C*07:02:01:97.

Two novel alleles HLA-DQB1*03:01:01:23 and DQB1*03:01:01:24 in a Konyak Naga individual from North-East India.

HLA-DQB1*03:01:01:07, intron 1 [1217(A→G)] and intron 2 [2138 (T→C)] substitutions generate HLA-DQB1*03:01:01:23 and HLA-DQB1*03:01:01:24, respectively.

Recognition of the novel HLA-DQB1*05:03:01:04 allele in an Angami individual from Nagaland, North-East India.

HLA-DQB1*05:03:01:04 differs from HLA-DQB1*05:03:01:01 by one nucleotide substitution at position 5075 (A>G).

Description of the novel null allele, HLA-DPA1*01:29N in a Lotha individual from Nagaland, North-East India.

A single nucleotide change in HLA-DPA1*01:03:01:01 results in the novel null allele, HLA-DPA1*01:29N.

HLA-C*04:01:01:78, a novel variant of HLA-C*04, detected in a Sumi individual from Nagaland, North-East India.

One nucleotide substitution (C > G) in 3'-UTR of HLA-C*04:01:01:01 results in the novel allele, HLA-C*04:01:01:78.

Discovery of the novel allele, HLA-C*03:04:01:38 in two individuals from the Ao tribe of Nagaland, North-East India.

One nucleotide substitution (C>T) in intron 1 of HLA-C*03:04:01:02 results in the novel allele, HLA-C*03:04:01:38.

HLA-C*07:06:01:06-A new HLA-C allele identified in an Ao tribal individual from Nagaland, North-East India.

Two nucleotide changes in the 3'untranslated region of HLA-C*07:06:01:01 results in the novel allele, HLA-C*07:06:01:06.

HLA-DPA1*02:01:01:13, a novel HLA-DPA1 allele, detected in an Ao tribal individual from Nagaland, North-East India.

Thirteen nucleotide substitutions in intron 1 of HLA-DPA1*02:01:01:09 results in a novel allele, HLA-DPA1*02:01:01:13.

A novel allele HLA-B*38:02:01:02, identified in an Angami individual from Nagaland, North-East India.

A single nucleotide change (C to T) in HLA-B*38:02:01 results in the novel allele, HLA-B*38:02:01:02.

A novel allele HLA-B*15:02:01:04, recognized in an individual from the Angami tribe, Nagaland, North-East India.

A single nucleotide change (T to C) in HLA-B*15:02:01:01 results in the novel allele, HLA-B*15:02:01:04.

Detection of the novel HLA-DQB1*03:404 allele in an Ao individual from Nagaland, North-East India.

One nucleotide substitution in codon 127 of HLA-DQB1*03:01:01:07 results in the novel allele, HLA-DQB1*03:404.

Characterization of the novel allele HLA-DPA1*02:01:01:12 from an Ao tribal individual from Nagaland, North-East India.

One nucleotide substitution (A>T) in intron 1 of HLA-DPA1*02:01:01:02 results in the novel allele, HLA-DPA1*02:01:01:12.

A silent mutation in codon 228 results in a novel allele HLA-C*04:06:03 in an Ao-Naga individual from North-East India.

One nucleotide substitution (C>T) in codon 228 of HLA-C*04:06:01 results in the novel allele, HLA-C*04:06:03.

The novel HLA-C*04:400 allele, identified in a Konyak-Naga tribal individual from North-East India.

One nucleotide substitution (G>A) in codon 41 of HLA-C*04:03:01:01 results in the novel allele, HLA-C*04:400.

Recognition of the novel HLA-A*11:01:01:25 allele in the tribal population of Nagaland, North-East India.

One nucleotide change (G>A) at intron 1 of HLA-A*11:01:01:01 results in the novel allele, HLA-A*11:01:01:25.

The HLA-B*13:01:01:03 allele characterized in four individuals from the tribal population of Nagaland, North-East India.

A single nucleotide change (G to T) in HLA-B*13:01:01:01 results in the novel allele, HLA-B*13:01:01:03.